ECL has clawed back ground this week — up 3.5% to $254.23 — but the options market has yet to fully release its defensive posture, even as the month-long selloff shows signs of stalling.
The options picture has shifted since last week's note, though not dramatically. The put/call ratio has eased from a two-standard-deviation peak to 0.73, now running roughly one standard deviation above its 20-day average of 0.66. That is still elevated. The move lower from the 0.79 reading of May 20 tracks the price recovery, but the PCR remains well above where it was in early May — when it sat below 0.60 — suggesting options traders are hedging more cautiously than before the selloff. The borrow market, as before, offers no additional signal: cost to borrow ticked up 16% on the week to 0.54%, but in absolute terms that remains negligible. Availability is effectively unlimited. Short interest itself is barely worth discussing — at 1.06% of the free float, it has drifted fractionally higher over the past month but remains too small to matter directionally.
The Street remains broadly constructive, but a quiet trimming of targets reflects the month's weakness. Jefferies lowered its target from $352 to $345 on May 20 while holding its Buy rating. Wells Fargo cut more aggressively, dropping from $285 to $260, though it remains at Equal-Weight. RBC Capital has reiterated Outperform with a $337 target twice this week. The consensus mean target is $317, around 25% above the current price, with 14 buys and 5 outperforms against 7 holds and no sells. That's a firmly bullish skew, though it should be noted the target range spans from $260 to $345 — a wide band that reflects genuine disagreement on how much of the macro uncertainty has already been priced in. Valuation multiples have compressed over the past month — the P/E has come in roughly 1.6 points to 28.6x, and the P/B has shed 0.6 turns to 6.1x — offering marginally better entry conditions than the highs but still well above sector norms.
The institutional register is anchored by Cascade Investment — the Bill Gates vehicle — holding 10.4% of shares, unchanged. BlackRock added roughly 217,000 shares as of April 30, and JPMorgan Asset Management added 730,000 — the most notable accumulation in the top-holder list. On the insider side, Lead Independent Director David MacLennan bought 1,000 shares on May 13 at $250.65, following an 800-share purchase on May 4 at $256.91. These are modest in dollar terms — under $250,000 combined — but notable for their timing at the lows of the recent drawdown, and they represent the only open-market buying in the recent trade history.
The last two earnings prints are worth noting for context. ECL fell 3.5% the day after its May 7 report and slid a further 5.5% over the following week. The April 28 release produced a similar pattern — down 4.2% on the day, down 3.8% over five days. That consistent post-earnings weakness argues that the stock's defensive profile doesn't fully insulate it from disappointment. The next earnings date is July 28.
What to watch: whether the put/call ratio continues to normalise toward its pre-drawdown range below 0.60, and whether the director's purchases mark a floor or merely slow the descent — the July 28 print will test both.
See the live data behind this article on ORTEX.
Open ECL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
